News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Promoting competition key for high cost medicines

Media release

Promoting competition key to improving patients’ access to high cost medicines

PHARMAC has announced its intention to test out a contestable fund for high cost medicines for rare disorders, which could be seeking proposals from pharmaceutical companies by the end of 2014.

Promoting competition among suppliers could be the key to improving patients’ access to high cost medicines for rare disorders, says chief executive Steffan Crausaz.

The fund is a response to concerns about access to these medicines that PHARMAC has been hearing from patients through forums and consultations in recent months.

“We’ve listened closely to these views, and thought about them carefully. Our thinking leads us to the view that the core problem is a lack of competition,” says Steffan Crausaz.

“We know competition leads to lower prices, and that’s an area where PHARMAC has an established track record. Our activities in promoting competition enable New Zealand to achieve some of the lowest prices for medicines in the world.”

“We think that by promoting competition among suppliers, prices will reduce and as a result, patients will get funded access to them. Ultimately, that’s what this fund is about.”

“Pharmaceutical suppliers tell us one of their main motivators is providing patients with access to their products. That’s something we certainly want to see, and I hope the industry takes this opportunity to help us find a way to make these medicines more available to patients.”

Steffan Crausaz says the new approach is possible within PHARMAC’s current operating framework, and would still involve PHARMAC seeking to get the best health outcomes for patients from the available funding for pharmaceuticals.

“PHARMAC will continue to look for the best health outcomes for patients, and the best value investments. The approach we intend to use will be consistent with the PHARMAC model and, importantly, will still enable us to continue to fund other new medicines for conditions that aren’t rare.”

PHARMAC has published a discussion paper on its website and is inviting comments from the public and industry on the contestable fund. These comments would help iron out some of the detail of how the fund would operate.

Steffan Crausaz says up to $5 million per year may be available, through funding that has already been budgeted but not likely to be used for the $8 million exceptions policy. Because this funding is already budgeted, it won't limit PHARMAC's ability to fund other treatments for less rare conditions.

Should PHARMAC request commercial proposals by the end of 2014, funding could begin in early 2015. The discussion document can be found on our website:www.pharmac.health.nz/link/high-cost-medicines.

Ends

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Max Rashbrooke: Review - The NZSO And Nature

This was a lovely, varied concert with an obvious theme based on the natural world. It kicked off with Mendelssohn's sparkling Hebrides Overture, which had a wonderfully taut spring right from the start, and great colour from the woodwinds, especially the clarinets. More>>

Scoop Review Of Books: Q&A: Prue Hyman On ‘Hopes Dashed?’

For Scoop Review of Books, Alison McCulloch interviewed Prue Hyman about her new book, part of the BWB Texts series, Hopes Dashed? The Economics of Gender Inequality More>>

Gordon Campbell: On Chuck Berry (And James Comey, And Bill English)

Back when many people were still treating rock’n’roll as a passing fad – was calypso going to be the new thing? – Chuck Berry knew that it had changed popular music forever. What is even more astonishing is that this 30-ish black r&b musician from a middle class family in St Louis could manage to recreate the world of white teenagers, at a time when the very notion of a “teenager” had just been invented. More>>

Howard Davis Review:
The Baroque Fusion Of L'arpeggiata

Named after a toccata by German composer Girolamo Kapsberger, L'Arpeggiata produces its unmistakable sonority mainly from the resonance of plucked strings, creating a tightly-woven acoustic texture that is both idiosyncratic and immediately identifiable. Director Christina Pluhar engenders this distinctive tonality associated with the ensemble she founded in 2000 by inviting musicians and vocalists from around the world to collaborate on specific projects illuminated by her musicological research. More>>

African Masks And Sculpture: Attic Discovery On Display At Expressions Whirinaki

Ranging from masks studded with nails and shards of glass to statues laden with magical metal, the works are from ethnic groups in nine countries ranging from Ivory Coast to the Democratic Republic of the Congo. More>>

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news